William E. Evans

60.5k total citations · 16 hit papers
386 papers, 34.0k citations indexed

About

William E. Evans is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, William E. Evans has authored 386 papers receiving a total of 34.0k indexed citations (citations by other indexed papers that have themselves been cited), including 214 papers in Public Health, Environmental and Occupational Health, 147 papers in Pediatrics, Perinatology and Child Health and 105 papers in Molecular Biology. Recurrent topics in William E. Evans's work include Acute Lymphoblastic Leukemia research (212 papers), Childhood Cancer Survivors' Quality of Life (109 papers) and Acute Myeloid Leukemia Research (35 papers). William E. Evans is often cited by papers focused on Acute Lymphoblastic Leukemia research (212 papers), Childhood Cancer Survivors' Quality of Life (109 papers) and Acute Myeloid Leukemia Research (35 papers). William E. Evans collaborates with scholars based in United States, Germany and Netherlands. William E. Evans's co-authors include Mary V. Relling, Ching‐Hon Pui, Howard L. McLeod, Eugene Y. Krynetski, Gaston K. Rivera, John T. Sandlund, Raul C. Ribeiro, Cheng Cheng, Wenjian Yang and James R. Downing and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

William E. Evans

370 papers receiving 33.0k citations

Hit Papers

Pharmacogenomics: Translating Functional Genomics into Ra... 1991 2026 2002 2014 1999 2006 2003 2007 1992 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
    1999 1.8k citations William E. Evans, Mary V. Relling profile →
  2. Treatment of Acute Lymphoblastic Leukemia
    2006 1.4k citations Ching‐Hon Pui, William E. Evans profile →
  3. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
    2003 1.3k citations William E. Evans et al. profile →
  4. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
    2007 1.2k citations Charles G. Mullighan, Elaine Coustan‐Smith et al. profile →
  5. Applied pharmacokinetics : principles of therapeutic drug monitoring
    1992 659 citations William E. Evans et al. profile →
  6. Acute Lymphoblastic Leukemia
    1998 639 citations Ching‐Hon Pui, William E. Evans profile →
  7. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
    2009 595 citations Monique L. den Boer, Meyling Cheok et al. profile →
  8. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
    2015 592 citations Ching‐Hon Pui, Jun J. Yang et al. Journal of Clinical Oncology profile →
  9. Pharmacogenomics in the clinic
    2015 554 citations Mary V. Relling, William E. Evans profile →
  10. Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia
    1991 523 citations Ching‐Hon Pui, Raul C. Ribeiro et al. profile →
  11. Moving towards individualized medicine with pharmacogenomics
    2004 510 citations William E. Evans, Mary V. Relling profile →
  12. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update
    2018 403 citations Mary V. Relling, Matthias Schwab et al. Clinical Pharmacology & Therapeutics profile →
  13. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
    2011 401 citations Mary V. Relling, William E. Evans et al. Clinical Pharmacology & Therapeutics profile →
  14. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
    2012 374 citations Ching‐Hon Pui, Charles G. Mullighan et al. Blood profile →
  15. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
    2014 345 citations Kristine R. Crews, James M. Hoffman et al. profile →
  16. Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia
    2015 306 citations Jun J. Yang, Wendy Landier et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William E. Evans United States 93 15.6k 11.3k 9.4k 7.4k 6.7k 386 34.0k
Mary V. Relling United States 97 14.5k 0.9× 12.3k 1.1× 8.6k 0.9× 6.5k 0.9× 7.6k 1.1× 381 33.5k
Ching‐Hon Pui United States 110 26.0k 1.7× 16.7k 1.5× 10.5k 1.1× 16.8k 2.3× 8.6k 1.3× 629 45.5k
Rob Pieters Netherlands 79 11.4k 0.7× 6.3k 0.6× 9.3k 1.0× 7.9k 1.1× 4.2k 0.6× 518 22.9k
Teri E. Klein United States 86 2.4k 0.2× 6.3k 0.6× 7.2k 0.8× 668 0.1× 4.8k 0.7× 362 30.2k
Howard L. McLeod United States 81 1.9k 0.1× 2.6k 0.2× 9.6k 1.0× 984 0.1× 10.1k 1.5× 481 26.6k
Jan H.M. Schellens Netherlands 91 1.3k 0.1× 3.2k 0.3× 16.1k 1.7× 2.1k 0.3× 22.6k 3.4× 882 41.1k
Alex Sparreboom United States 86 1.1k 0.1× 3.3k 0.3× 8.9k 0.9× 2.0k 0.3× 14.2k 2.1× 408 24.4k
Mark J. Ratain United States 74 1.6k 0.1× 2.1k 0.2× 9.1k 1.0× 966 0.1× 10.2k 1.5× 532 23.0k
Giovanni Scambia Italy 89 3.2k 0.2× 2.3k 0.2× 11.1k 1.2× 1.3k 0.2× 12.4k 1.8× 2.0k 49.2k
Roger Williams United Kingdom 106 1.1k 0.1× 1.5k 0.1× 14.2k 1.5× 2.1k 0.3× 3.4k 0.5× 830 45.7k

Countries citing papers authored by William E. Evans

Since Specialization
Citations

This map shows the geographic impact of William E. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William E. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William E. Evans more than expected).

Fields of papers citing papers by William E. Evans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William E. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William E. Evans. The network helps show where William E. Evans may publish in the future.

Co-authorship network of co-authors of William E. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of William E. Evans. A scholar is included among the top collaborators of William E. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William E. Evans. William E. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Shawn H. R., Wenjian Yang, Kathryn G. Roberts, et al.. (2023). Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL. Journal of Clinical Oncology. 41(35). 5422–5432. 7 indexed citations
2.
Diedrich, Jonathan D., Yang Zhang, Kelly R. Barnett, et al.. (2022). Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia. Leukemia. 36(10). 2374–2383. 3 indexed citations
3.
Lucafò, Marianna, Simona Granata, Erik Bonten, et al.. (2020). Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid‐resistant from glucocorticoid‐sensitive idiopathic nephrotic syndrome patients. Clinical and Translational Science. 14(3). 964–975. 14 indexed citations
4.
López-López, Elixabet, Robert J. Autry, Colton Smith, et al.. (2020). Pharmacogenomics of intracellular methotrexate polyglutamates in patients’ leukemia cells in vivo. Journal of Clinical Investigation. 130(12). 6600–6615. 20 indexed citations
5.
Xu, Heng, Xujie Zhao, Deepa Bhojwani, et al.. (2019). ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. Clinical Cancer Research. 26(1). 256–264. 21 indexed citations
6.
Paugh, Steven W., Ju Bao, Christy R. Grace, et al.. (2016). MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression. PLoS Computational Biology. 12(2). e1004744–e1004744. 60 indexed citations
7.
Bhojwani, Deepa, Noah D. Sabin, Deqing Pei, et al.. (2014). Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 32(9). 949–959. 242 indexed citations
8.
Roberts, Kathryn G., Deqing Pei, Dario Campana, et al.. (2014). Outcomes of Children With BCR-ABL1 –Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease. Journal of Clinical Oncology. 32(27). 3012–3020. 165 indexed citations
9.
Bhatia, Ravi, Wendy Landier, Lindsey Hageman, et al.. (2014). 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 124(15). 2345–2353. 152 indexed citations
10.
Hoffman, James M., Cyrine E. Haidar, Mark R. Wilkinson, et al.. (2014). PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 166(1). 45–55. 205 indexed citations
11.
Panetta, John C., Steven W. Paugh, & William E. Evans. (2013). Mathematical modeling of folate metabolism. WIREs Systems Biology and Medicine. 5(5). 603–613. 6 indexed citations
12.
Veer, Arian van der, Esmé Waanders, Rob Pieters, et al.. (2013). Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 122(15). 2622–2629. 187 indexed citations
13.
Ramsey, Laura B., John C. Panetta, Colton Smith, et al.. (2012). Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 121(6). 898–904. 157 indexed citations
14.
Kawedia, Jitesh D., Sue C. Kaste, Deqing Pei, et al.. (2010). Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 117(8). 2340–2347. 186 indexed citations
15.
Krishnamurthy, Partha, Matthias Schwab, Kazumasa Takenaka, et al.. (2008). Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity. Cancer Research. 68(13). 4983–4989. 116 indexed citations
16.
Jones, Terreia S., Wentao Yang, William E. Evans, & Mary V. Relling. (2007). Using HapMap Tools in Pharmacogenomic Discovery: The Thiopurine Methyltransferase Polymorphism. Clinical Pharmacology & Therapeutics. 81(5). 729–734. 25 indexed citations
17.
Evans, William E.. (2004). Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy. Therapeutic Drug Monitoring. 26(2). 186–191. 129 indexed citations
18.
Rivera, Gaston K., Yinmei Zhou, Michael L. Hancock, et al.. (2004). Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer. 103(2). 368–376. 64 indexed citations
19.
Krynetski, Eugene Y., Natalia F. Krynetskaia, Amy Gallo, K. Gopal Murti, & William E. Evans. (2001). A Novel Protein Complex Distinct from Mismatch Repair Binds Thioguanylated DNA. Molecular Pharmacology. 59(2). 367–374. 2 indexed citations
20.
Krynetski, Eugene Y. & William E. Evans. (1999). Pharmacogenetics as a Molecular Basis for Individualized Drug Therapy: The Thiopurine S-methyltransferase Paradigm. Pharmaceutical Research. 16(3). 342–349. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary V. Relling Breakdown of academic impact, for papers by Ching‐Hon Pui Breakdown of academic impact, for papers by Rob Pieters Breakdown of academic impact, for papers by Teri E. Klein Breakdown of academic impact, for papers by Howard L. McLeod Breakdown of academic impact, for papers by Jan H.M. Schellens Breakdown of academic impact, for papers by Alex Sparreboom Breakdown of academic impact, for papers by Mark J. Ratain Breakdown of academic impact, for papers by Giovanni Scambia Breakdown of academic impact, for papers by Roger Williams
Rankless by CCL
2026